Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] activity
adverse event
allergic reaction
anti-SARS-CoV-2
anti-SARS-CoV-2 antibody
Anti-SARS-CoV-2 plasma
Anti-viral
blinded
Blood
blood product
center
Chest radiography
Clinical improvement
Clinical outcome
clinical status
clinical trial
clinician
collected
Columbia University
control arm
convalescent plasma
coronavirus
COVID-19
COVID-19 symptom
criteria
cumulative
Date
defined
Dilution
discharge
dissemination
Donor
ECMO
Efficacy
Efficacy and safety
element
evaluate
Evaluating
Evidence
extracorporeal membrane oxygenation
hazard
hazard ratio
HBV
HCV
HIV
hospital
Hospitalized
hospitalized patient
IgA deficiency
immune
incidence
include
Infection
Influenza
Invasive mechanical ventilation
mechanical ventilation
multi-organ failure
nasopharyngeal
Nasopharyngeal swab
New York
Non-invasive
number
objective
occur
oropharyngeal swab
outcome
oxygen saturation
participant
Participants
patients hospitalized
PCR test
PCR-negative
per-protocol analysis
peripheral capillary
plasma
platform
post-hoc analysis
Pregnancy
primary endpoint
protocol
randomization
Randomized
Randomized controlled trial
randomized, controlled trial
randomly permuted block
receive
Registered
Remdesivir
requiring high-flow oxygen
requiring supplemental oxygen
Research
Respiratory failure
retrospective
Ritonavir
safety endpoint
Sample size
SARS-CoV-2
SARS-CoV-2 antibody
SARS-COV-2 infection
screened
Serious Adverse Event
seven-point ordinal scale
severe COVID-19
severe SARS-CoV-2
severely ill adult
single-center
spike trimer
SpO2
status
study participant
study period
Study protocol
supplemental oxygen
tested
therapy
transfused
Treatment
treatment for COVID-19
Trial
undergo
USA
Version
Volunteer
Wald test
website
with COVID-19
World Health Organization
ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter